Fulgent Genetics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was USD 67.7 million compared to USD 251.67 million a year ago. Net loss was USD 23.83 million compared to net income of USD 104.34 million a year ago.

Basic loss per share from continuing operations was USD 0.8 compared to basic earnings per share from continuing operations of USD 3.48 a year ago. Diluted loss per share from continuing operations was USD 0.8 compared to diluted earnings per share from continuing operations of USD 3.34 a year ago.